ERBB2 and glioblastoma: Preclinical studies of glioblastoma have demonstrated that CRISPR-edited CAR-T cells targeting both Human Epidermal Growth Factor Receptor 2 (HER2) and IL13Rα2 antigens can overcome immune evasion by significantly reducing tumor growth and improving tumor control (61).